Tracers / [11C]MTP38
[11C]MTP38
Also written as [11C]MTP38; [C-11]MTP38
- Radionuclide
- C-11 t½ 20.36 min
- Modality
- PET
- Production route
- —
- Stage
- first-in-human
- Syntheses indexed
- 1
What it is
- Compound class
- PET ligand (radiolabeled phosphodiesterase 7 inhibitor, triazolopyrazine carbonitrile derivative)
- Target / mechanism
- Phosphodiesterase 7 (PDE7) PMID 33674894
- Clinical application
- Healthy male volunteers; investigation of neuropsychiatric diseases involving PDE7 dysfunction PMID 33566152
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | 33 ± 5.5% yes | >97% | — | 35122288 2022 J Labelled Comp Radiopharm Radiosynthesis of [11 C]MTP38 was performed using an automated 11 C-labeling synthesizer developed in-house within 40 min after the end of irradiation. — relatively high radiochemical yield (33 ± 5.5% based on [11 C]CO2 at the end of irradiation, decay-corrected, n = 15) |
Need this precursor?We can point you to suppliers for [11C]MTP38, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [11C]MTP38.
Get in touchNotes
Added from reverse module search (stage 6); 1 article(s) with C-11.